)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
VolitionRX
VolitionRX (VNRX) investor relations material
VolitionRX Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary28 Aug, 2026
Company overview and business model
Multi-national epigenetics company developing blood tests for early detection and monitoring of diseases like cancer and sepsis using patented nucleosome-based technologies.
Product portfolio includes Nu.Q® Vet (canine cancer screening), Nu.Q® NETs (sepsis detection), Nu.Q® Discover (nucleosome profiling), and Nu.Q® Cancer (cancer diagnostics and monitoring).
Operations span Belgium, California, London, and Nevada, with approximately 60 employees and collaborations with academic, clinical, and industry partners.
Financial performance and metrics
Recent equity sales through an at-the-market program raised approximately $2.1 million in net proceeds between June and August 2026.
June 2026 public offering raised net proceeds of about $4.1 million through the sale of shares and warrants.
Non-compliance with a market capitalization covenant in May 2026 increased outstanding principal on convertible notes by $623,333.
Use of proceeds and capital allocation
No proceeds from the resale of shares by the selling stockholder; all proceeds go to the selling stockholder.
Company covers registration-related expenses, excluding brokerage commissions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from VolitionRX
- Expansion into new disease areas and global licensing drive growth, with clinical adoption expected in 2026.VNRX
Corporate presentation - Asset-light, licensing-driven growth targets multi-billion dollar diagnostics markets with strong IP.VNRXCorporate presentation
- First half 2026 revenue up 112% with major clinical, licensing, and cost reduction progress.VNRXQ2 2026
- Platform-agnostic diagnostics and licensing drive growth in cancer, sepsis, and animal health.VNRXCorporate presentation
- 3.3 million shares registered for resale by a noteholder, with no proceeds to the company.VNRXRegistration filing
- Nu.Q blood tests enable rapid, cost-effective cancer detection and monitoring worldwide.VNRXStudy update
- Shareholders will vote on directors, auditor, compensation, share reduction, and a new incentive plan.VNRXProxy filing
- Major licensing deals, global launches, and clinical milestones drive growth in cancer and sepsis diagnostics.VNRXCorporate presentation
- Q1 2026 revenue reached $1.0M, but net loss increased amid clinical and licensing progress.VNRXQ1 2026
Next VolitionRX earnings date
Q3 202613 Nov, 2026
VolitionRX
Next VolitionRX earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage